HOBOKEN, N.J., July 16, 2018 /PRNewswire/ -- Octapharma USA was the exclusive sponsor of the VWD Connect Foundation Conference, a four-day national program for patients with Type 3/severe Von Willebrand Disease (VWD), recently held at the PGA National Resort & Spa in Palm Beach Gardens, Florida.
"We brought together patients and their guests with a world class group of physicians and medical professionals in a safe and relaxed environment for making lifetime connections and sharing educational information," said conference organizer Jeanette Cesta, Executive Director of the VWD Connect Foundation. "We thank Octapharma USA for again supporting the conference with an educational grant and helping us create a truly special event for the Type 3/severe VWD community."
VWD affects up to 1 percent of the U.S. population. Type 3 VWD is the rarest and most severe form of the condition.
"Octapharma USA was honored to have the opportunity to fund this great conference for the Type 3/severe VWD community," said Octapharma USA President Flemming Nielsen. "We are committed to supporting bleeding disorders patients with life-saving therapies and unique programs that enable patients and families to better manage their illness. The second conference was a great success and we are pleased that Octapharma was again the only manufacturer to sponsor this wonderful event."
Educational information and other resources were provided on various medical issues, such as treatment alternatives, joint health, symptoms and diagnosis. Emotional and social topics on the agenda included family and professional relationships, challenges of loss and depression, disclosure issues, and positive coping strategies.
Physicians, healthcare providers specializing in bleeding disorders, geneticists, health educators, nurses, physical therapists, and social workers were among the many professional resources available to conference attendees. For complete conference information, please visit www.VWDConnect.org.
About the VWD Connect Foundation
VWD Connect Foundation is a Florida-based 501(c)3 non-profit organization created to serve the bleeding disorder community, focusing on severe von Willebrand Disease. It provides education and connection for patients and families, and supports research that will benefit the von Willebrand Disease community.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 7,600 people worldwide to support the treatment of patients in over 113 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company's American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.
WIL-0161
SOURCE Octapharma USA